Loading news...
Stock News Stocks slide as oil tops $100: The S&P 500 fell 0.61% to a 2026 low and notched a third straight weekly decline as Brent closed above $100 and WTI ne
Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population1. The approval of a distinct biologic option for pediatric patients living with HS allows treatment to be tailored to the individual and establishes Cosentyx as a meaningful addition to the treatment landscape1-13.
Stock News Futures steady after selloff: SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Invesco QQQ Trust (QQQ) pointed to
Stock News IEA warns of historic oil disruption: Chevron (CVX) and Exxon Mobil (XOM) advanced as the International Energy Agency said Iran's effective closure o
Stock News Oil tops $100 as Hormuz attacks jolt markets: Chevron (CVX) and peers rallied after Brent briefly exceeded $100 a barrel amid Iranian attacks that ch
Stock News Inflation steady before oil shock: February CPI rose 2.4% year over year and core 2.5%, in line with forecasts, but markets are looking past the repo
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1 554 shareholders were present at the meeting held in Basel, representing approximately 59.15% of the issued shares of Novartis. With a dividend increase of 5.7% to CHF 3.70 per share, shareholders approved the 29th consecutive increase, resulting in a dividend yield of 3.0%¹. Payment of the 2025 dividend will be made from March 12, 2026. Election of a new member of the Board of Directors Shareholders have re-elected Giovanni Caforio as member of the Board of Directors and Board Chair. In addition, shareholders elected Charles Swanton as new member of the Board of Directors. Daniel Hochstrasser did not stand for re-election. All other members of the Board of Directors have been re-elected. All elections and re-elections pertain to a term lasting until the completion of the next AGM. Shareholders also re-elected all current members of the Compensation Committee and elected Elizabeth McNally as new member of the Compensation Committee, each until the end of the next AGM. With his re-election, Simon Moroney remains Chair of the Committee in line with the designation from the Board of Directors. Reduction of share capital Shareholders approved the proposal by the Board of Directors to cancel 77 602 358 shares and to reduce the share capital accordingly by CHF 38 025 155.42 (from CHF 1 035 086 714.83 to CHF 997 061 559.41). Compensation for the Board of Directors and the Executive Committee In two separate binding votes, shareholders approved the total maximum aggregate amount of compensation for the Board of Directors, covering the period from the 2026 AGM to the 2027 AGM, and the total maximum aggregate amount of compensation for the Executive Committee for the 2027 financial year. Shareholders further endorsed the 2025 Compensation Report in an advisory vote. Resolutions For a detailed listing of all resolutions at the 2026 AGM, please visit: https://novartis.com/agm Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “future,” “proposed,” “will,” or similar terms, or by express or implied discussions regarding the potential future impact of the matters described in this press release, including the future commercial performance of Novartis, future reductions in share capital, the annual re-election and election of members of the Board of Directors and committees of the Board, and votes on compensation for the members of the Board of Directors and the Executive Committee. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee as to the ultimate outcome of the matters described in this press release or their potential impact on Novartis. In particular, our expectations regarding these matters could be affected by, among other things, uncertainties concerning: global healthcare cost containment; the success of key products, commercial priorities and strategy; research and development of new products; our ability to obtain or maintain proprietary intellectual property protection; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence; potential significant breaches of information security; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; and other risks and factors referred to in Novartis AG's most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . References 1. Based on the Novartis SIX Swiss Exchange closing share price of CHF 124.82 on March 5, 2026
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells.
Banco Santander S.A. lowered its stake in shares of Novartis AG (NYSE: NVS) by 51.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,286 shares of the company's stock after selling 32,075 shares during the period. Banco Santander S.A.'s
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030 Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib. The opinion supports its use as an oral treatment for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1‑antihistamine treatment. “The introduction of remibrutinib represents a major advancement, providing clinicians with an oral Bruton's tyrosine kinase inhibitor (BTKi) treatment, with improvements in symptoms observed as early as Week 1,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité Universitätsmedizin Berlin. “CSU continues to impose a substantial unmet medical need, as many patients struggle to achieve adequate disease control with currently available therapies.” The positive CHMP opinion is supported by results from the pivotal REMIX-1 and REMIX-2 Phase III trials. Remibrutinib showed improvements in itch and hives as early as Week 1, with benefits sustained through Week 521. Improvements in quality of life and sleep were also observed early in treatment 1. Remibrutinib was well tolerated and demonstrated a favorable safety profile, including no liver safety concerns across both studies through Week 521. “People living with CSU often endure years of frustration, and difficulty being taken seriously. For many, the unpredictable itch flare‑ups can make it hard to sleep, focus on daily responsibilities, or even perform their jobs at times,” said Tonya Winders, President and CEO, Global Allergy & Airways Patient Platform (GAAPP). “The arrival of a new oral treatment option brings us one step closer to ensuring that every person has the opportunity to live fully again.” “Today's positive CHMP opinion is an important step towards addressing the significant unmet needs of adults living with CSU in Europe,” said Patrick Horber, M.D., President, International, Novartis. “We will continue to collaborate with regulatory authorities globally to make this important medicine, discovered and developed by Novartis, available to patients who need it most.” Following the CHMP recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About remibrutinib Remibrutinib is a highly selective, oral BTK inhibitor that blocks the BTK pathway involved in the release of histamine, a key driver of itchy hives (wheals) and swelling5-7. By reducing histamine release, remibrutinib helps relieve the symptoms of chronic spontaneous urticaria (CSU)8,9. In the US and China, remibrutinib is approved for the treatment of adult patients with CSU who have an inadequate response to H1-antihistamines, under the brand name Rhapsido ® . Remibrutinib has shown positive topline results in chronic inducible urticaria (CIndU) across the three most prevalent subtypes in the pivotal Phase III RemIND trial. It is also being investigated in other immune-mediated conditions, such as hidradenitis suppurativa (HS) and food allergy, in addition to other indications in the company's Neuroscience portfolio10 - 14.
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and temperature controls, potentially puts patients at risk, the suit said.
Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwide.
Fox Run Management L.L.C. purchased a new position in Novartis AG (NYSE: NVS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,349 shares of the company's stock, valued at approximately $1,584,000. Other hedge funds and other institutional investors have also recently
Novartis' business is resilient, as evidenced by its ability to grow sales despite a major patent cliff. The Swiss healthcare giant's income program is another great attraction for long-term investors.
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases. New analyses on the impact of Rhapsido on disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 trials in CSU will be presented. Additionally, the first presentation of Phase II FA data for remibrutinib, focusing on IgE‑mediated peanut allergy, will be featured in an oral session. Plans are in progress to begin the Phase III program in FA in 2026. “These food allergy (FA) data further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases, complementing the recent FDA approval in chronic spontaneous urticaria (CSU) and underscoring its broader therapeutic potential,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. "Our priority is advancing therapies for patients who have few alternatives and expanding the reach of innovative medicines to transform care across multiple, high-need disease areas." Regulatory reviews for remibrutinib for the treatment of CSU are underway in several regions, including the European Union and Japan. In addition to FA, remibrutinib is in clinical development for chronic inducible urticaria (CIndU) and hidradenitis suppurativa (HS). FDA submission for remibrutinib in symptomatic dermographism, the most prevalent type of CIndU, was completed in Q4 2025. Additionally, positive topline results were announced for the remaining two arms of the CIndU Phase III RemIND trial. In the coming months, the full data set will be submitted to health authorities globally, and the RemIND trial findings will be presented at upcoming medical congresses. Abstracts accepted by AAAAI include:
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.